Prostate Cancer — Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer
Citation(s)
Neoadjuvant Hormonal Ablation, Imatinib Mesylate and Docetaxel Followed by Radical Prostatectomy for High-Risk Localized Prostate Cancer